Paolo Fusar-Poli

List of Publications by Citations

467 papers	26,396 citations	84 h-index	148 g-index
518 ext. papers	32,728 ext. citations	6.1 avg, IF	7.55 L-index

#	Paper	IF	Citations
467	Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. *Lancet Psychiatry,the*, **2020**, 7, 611-627	23.3	1004
466	Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. *Archives of General Psychiatry*, **2012**, 69, 220-9		983
465	The psychosis high-risk state: a comprehensive state-of-the-art review. *JAMA Psychiatry*, **2013**, 70, 107-20	14.5	965
464	Functional atlas of emotional faces processing: a voxel-based meta-analysis of 105 functional magnetic resonance imaging studies. *Journal of Psychiatry and Neuroscience*, **2009**, 34, 418-32	4.5	859
463	Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. *Neuropsychopharmacology*, **2010**, 35, 764-74	8.7	481
462	Cognitive functioning in prodromal psychosis: a meta-analysis. *Archives of General Psychiatry*, **2012**, 69, 562-71		454
461	Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis. *Schizophrenia Bulletin*, **2014**, 40, 120-31	1.3	402
460	Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials. *Schizophrenia Bulletin*, **2015**, 41, 892-9	1.3	359
459	Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. *Neuroscience and Biobehavioral Reviews*, **2013**, 37, 1680-91	9	356
458	Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. *Archives of General Psychiatry*, **2009**, 66, 95-105		331
457	Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. *Journal of Psychopharmacology*, **2011**, 25, 121-30	4.6	304
456	Cannabis and anxiety: a critical review of the evidence. *Human Psychopharmacology*, **2009**, 24, 515-23	2.3	303
455	Altering the course of schizophrenia: progress and perspectives. *Nature Reviews Drug Discovery*, **2016**, 15, 485-515	64.1	284
454	Publication and other reporting biases in cognitive sciences: detection, prevalence, and prevention. *Trends in Cognitive Sciences*, **2014**, 18, 235-41	14	277
453	Neuroanatomy of vulnerability to psychosis: a voxel-based meta-analysis. *Neuroscience and Biobehavioral Reviews*, **2011**, 35, 1175-85	9	275
452	Heterogeneity of Psychosis Risk Within Individuals at Clinical High Risk: A Meta-analytical Stratification. *JAMA Psychiatry*, **2016**, 73, 113-20	14.5	270
451	Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. *PLoS ONE*, **2013**, 8, e55821	3.7	260

432	White matter alterations in early stages of schizophrenia: a systematic review of diffusion tensor imaging studies. *Journal of Neuroimaging*, **2014**, 24, 101-10	2.8	166
431	Neuroimaging in cannabis use: a systematic review of the literature. *Psychological Medicine*, **2010**, 40, 383-98	6.9	166
430	Induction of psychosis by 9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. *Archives of General Psychiatry*, **2012**, 69, 27-36		165
429	Dopaminergic basis of salience dysregulation in psychosis. *Trends in Neurosciences*, **2014**, 37, 85-94	13.3	162
428	Superior temporal lobe dysfunction and frontotemporal dysconnectivity in subjects at risk of psychosis and in first-episode psychosis. *Human Brain Mapping*, **2009**, 30, 4129-37	5.9	159
427	Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. *Biological Psychiatry*, **2008**, 64, 966-73	7.9	159
426	Outreach and support in south London (OASIS), 2001-2011: ten years of early diagnosis and treatment for young individuals at high clinical risk for psychosis. *European Psychiatry*, **2013**, 28, 315-26	6	153
425	Laterality effect on emotional faces processing: ALE meta-analysis of evidence. *Neuroscience Letters*, **2009**, 452, 262-7	3.3	151
424	Development and Validation of a Clinically Based Risk Calculator for the Transdiagnostic Prediction of Psychosis. *JAMA Psychiatry*, **2017**, 74, 493-500	14.5	150
423	Lessons learned from the psychosis high-risk state: towards a general staging model of prodromal intervention. *Psychological Medicine*, **2014**, 44, 17-24	6.9	149
422	Antipsychotics'effects on blood levels of cytokines in schizophrenia: a meta-analysis. *Schizophrenia Research*, **2013**, 151, 43-7	3.6	148
421	The Dark Side of the Moon: Meta-analytical Impact of Recruitment Strategies on Risk Enrichment in the Clinical High Risk State for Psychosis. *Schizophrenia Bulletin*, **2016**, 42, 732-43	1.3	144
420	Prevention of Psychosis: Advances in Detection, Prognosis, and Intervention. *JAMA Psychiatry*, **2020**, 77, 755-765	14.5	143
419	At risk for schizophrenic or affective psychoses? A meta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk. *Schizophrenia Bulletin*, **2013**, 39, 923-32	1.3	143
418	Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis. *American Journal of Psychiatry*, **2012**, 169, 264-72	11.9	143
417	Ten simple rules for conducting umbrella reviews. *Evidence-Based Mental Health*, **2018**, 21, 95-100	11.1	135
416	Co-occurring mental and substance abuse disorders: a review on the potential predictors and clinical outcomes. *Psychiatry Research*, **2011**, 186, 159-64	9.9	135
415	Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis. *World Psychiatry*, **2018**, 17, 196-209	14.4	134

414	Neurophysiological effects of acute oxytocin administration: systematic review and meta-analysis of placebo-controlled imaging studies. *Journal of Psychiatry and Neuroscience*, **2015**, 40, E1-22	4.5	131
413	Brain structural abnormalities at the onset of schizophrenia and bipolar disorder: a meta-analysis of controlled magnetic resonance imaging studies. *Current Pharmaceutical Design*, **2012**, 18, 486-94	3.3	129
412	Neural correlates of executive function and working memory in the 'at-risk mental state'. *British Journal of Psychiatry*, **2009**, 194, 25-33	5.4	128
411	The Clinical High-Risk State for Psychosis (CHR-P), Version II. *Schizophrenia Bulletin*, **2017**, 43, 44-47	1.3	125
410	Transdiagnostic psychiatry: a systematic review. *World Psychiatry*, **2019**, 18, 192-207	14.4	123
409	Basic symptoms and the prediction of first-episode psychosis. *Current Pharmaceutical Design*, **2012**, 18, 351-7	3.3	121
408	Functional neuroimaging in schizophrenia: diagnosis and drug discovery. *Trends in Pharmacological Sciences*, **2008**, 29, 91-8	13.2	120
407	Prognosis of Brief Psychotic Episodes: A Meta-analysis. *JAMA Psychiatry*, **2016**, 73, 211-20	14.5	119
406	Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. *Molecular Psychiatry*, **2021**,	15.1	116
405	Prevalence of self-reported childhood abuse in psychosis: a meta-analysis of retrospective studies. *Psychiatry Research*, **2013**, 210, 8-15	9.9	113
404	Prevalence and Psychosocial Correlates of Mental Health Outcomes Among Chinese College Students During the Coronavirus Disease (COVID-19) Pandemic. *Frontiers in Psychiatry*, **2020**, 11, 803	5	111
403	Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol. *International Journal of Neuropsychopharmacology*, **2010**, 13, 421-32	5.8	109
402	Diagnostic Stability of ICD/DSM First Episode Psychosis Diagnoses: Meta-analysis. *Schizophrenia Bulletin*, **2016**, 42, 1395-1406	1.3	106
401	Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis. *Archives of General Psychiatry*, **2011**, 68, 881-90		106
400	Oligodendroglial alterations and the role of microglia in white matter injury: relevance to schizophrenia. *Developmental Neuroscience*, **2013**, 35, 102-29	2.2	101
399	Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an FMRI study. *Neuropsychopharmacology*, **2011**, 36, 1340-8	8.7	101
398	Attenuated psychosis syndrome: ready for DSM-5.1?. *Annual Review of Clinical Psychology*, **2014**, 10, 155-92	22.5	99
397	BDNF Val66Met polymorphism and hippocampal volume in neuropsychiatric disorders: A systematic review and meta-analysis. *Neuroscience and Biobehavioral Reviews*, **2015**, 55, 107-18	9	98

378	Potential reporting bias in fMRI studies of the brain. *PLoS ONE*, **2013**, 8, e70104	3.7	80
377	Altered brain function directly related to structural abnormalities in people at ultra high risk of psychosis: longitudinal VBM-fMRI study. *Journal of Psychiatric Research*, **2011**, 45, 190-8	5.2	79
376	Environmental risk factors and biomarkers for autism spectrum disorder: an umbrella review of the evidence. *Lancet Psychiatry,the*, **2019**, 6, 590-600	23.3	78
375	F94. EFFECTS OF OXYTOCIN ON NEUROCHEMICAL METABOLITES IN PSYCHOSIS RISK. *Schizophrenia Bulletin*, **2019**, 45, S289-S290	1.3	78
374	O6.5. INVESTIGATING VARIABLES FROM THE NAPLS RISK CALCULATOR FOR PSYCHOSIS IN THE EU-GEI HIGH RISK STUDY. *Schizophrenia Bulletin*, **2019**, 45, S177-S178	1.3	78
373	34. IMPROVING THE DETECTION OF INDIVIDUALS AT RISK OF PSYCHOSIS. *Schizophrenia Bulletin*, **2018**, 44, S55-S56	1.3	78
372	F256. CAN WE REDUCE THE DURATION OF UNTREATED PSYCHOSIS?. *Schizophrenia Bulletin*, **2018**, 44, S323-S323	1.3	78
371	S149. EFFECTS OF INTRANASAL OXYTOCIN ON RESTING CEREBRAL BLOOD FLOW IN PEOPLE AT ULTRA-HIGH RISK FOR PSYCHOSIS. *Schizophrenia Bulletin*, **2018**, 44, S383-S383	1.3	78
370	T109. TRAVERSING THE TRANSDIAGNOSTIC GAP BETWEEN DEPRESSION, MANIA AND PSYCHOSIS WITH NATURAL LANGUAGE PROCESSING. *Schizophrenia Bulletin*, **2020**, 46, S272-S273	1.3	78
369	S154. TOBACCO SMOKING AND CLINICAL HIGH RISK: A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EVIDENCE. *Schizophrenia Bulletin*, **2020**, 46, S94-S95	1.3	78
368	T127. GENDER DIFFERENCES IN CLINICAL PRESENTATION AND ILLICIT SUBSTANCE USE DURING FIRST EPISODE PSYCHOSIS: AN ELECTRONIC CASE REGISTER NATURAL LANGUAGE PROCESSING ANALYSIS. *Schizophrenia Bulletin*, **2020**, 46, S278-S279	1.3	78
367	34.2 IMPROVING THE DETECTION OF INDIVIDUALS AT RISK OF PSYCHOSIS IN SECONDARY MENTAL HEALTH CARE. *Schizophrenia Bulletin*, **2018**, 44, S56-S57	1.3	78
366	T122. UNMET NEEDS IN PATIENTS WITH ACUTE TRANSIENT PSYCHOTIC DISORDERS (ATPD): ANALYSIS OF PATHWAYS TO CARE: AN 8 YEARS FOLLOW-UP STUDY. *Schizophrenia Bulletin*, **2018**, 44, S162-S163	1.3	78
365	S126. GOOD OUTCOME IN INDIVIDUALS AT ULTRA-HIGH RISK (UHR) OF DEVELOPING PSYCHOSIS: A DELPHI STUDY. *Schizophrenia Bulletin*, **2018**, 44, S374-S374	1.3	78
364	Social dysfunction predicts two years clinical outcome in people at ultra high risk for psychosis. *Journal of Psychiatric Research*, **2010**, 44, 294-301	5.2	77
363	Can antidepressants prevent psychosis?. *Lancet, The*, **2007**, 370, 1746-8	40	77
362	Psychopathological symptoms in child and adolescent migraine and tension-type headache: a meta-analysis. *Cephalalgia*, **2013**, 33, 112-22	6.1	76
361	Whither the attenuated psychosis syndrome?. *Schizophrenia Bulletin*, **2012**, 38, 1130-4	1.3	74

360	Towards a Standard Psychometric Diagnostic Interview for Subjects at Ultra High Risk of Psychosis: CAARMS versus SIPS. *Psychiatry Journal*, **2016**, 2016, 7146341	2.4	74
359	Affective temperamental profiles are associated with white matter hyperintensity and suicidal risk in patients with mood disorders. *Journal of Affective Disorders*, **2011**, 129, 47-55	6.6	73
358	Association of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review. *JAMA Psychiatry*, **2019**, 76, 1241-1255	14.5	72
357	Is cannabis neurotoxic for the healthy brain? A meta-analytical review of structural brain alterations in non-psychotic users. *Psychiatry and Clinical Neurosciences*, **2013**, 67, 483-92	6.2	72
356	Brain connectivity abnormalities predating the onset of psychosis: correlation with the effect of medication. *JAMA Psychiatry*, **2013**, 70, 903-12	14.5	72
355	Prenatal and perinatal risk and protective factors for psychosis: a systematic review and meta-analysis. *Lancet Psychiatry,the*, **2020**, 7, 399-410	23.3	69
354	Can We Reduce the Duration of Untreated Psychosis? A Systematic Review and Meta-Analysis of Controlled Interventional Studies. *Schizophrenia Bulletin*, **2018**, 44, 1362-1372	1.3	68
353	Tracking cerebral white matter changes across the lifespan: insights from diffusion tensor imaging studies. *Journal of Neural Transmission*, **2013**, 120, 1369-95	4.3	68
352	Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. *International Clinical Psychopharmacology*, **2013**, 28, 57-66	2.2	67
351	Efficacy and Acceptability of Interventions for Attenuated Positive Psychotic Symptoms in Individuals at Clinical High Risk of Psychosis: A Network Meta-Analysis. *Frontiers in Psychiatry*, **2018**, 9, 187	5	64
350	Neuroanatomical markers of genetic liability to psychosis and first episode psychosis: a voxelwise meta-analytical comparison. *World Journal of Biological Psychiatry*, **2014**, 15, 219-28	3.8	63
349	What Causes the Onset of Psychosis in Individuals at Clinical High Risk? A Meta-analysis of Risk and Protective Factors. *Schizophrenia Bulletin*, **2020**, 46, 110-120	1.3	63
348	Cannabidiol as a potential treatment for psychosis. *European Neuropsychopharmacology*, **2014**, 24, 51-64	1.2	62
347	Ten years of "extended" life: quality of life among heart transplantation survivors. *Transplantation*, **2004**, 78, 257-63	1.8	62
346	Serotonin transporter in Parkinson's disease: A meta-analysis of positron emission tomography studies. *Annals of Neurology*, **2017**, 81, 171-180	9.4	60
345	Cannabis use and transition to psychosis in people at ultra-high risk. *Psychological Medicine*, **2014**, 44, 2503-12	6.9	60
344	Altered prefrontal and hippocampal function during verbal encoding and recognition in people with prodromal symptoms of psychosis. *Schizophrenia Bulletin*, **2011**, 37, 746-56	1.3	60
343	Speed of Psychosis Progression in People at Ultra-High Clinical Risk: A Complementary Meta-analysis. *JAMA Psychiatry*, **2015**, 72, 622-3	14.5	58

342	Mapping prodromal psychosis: a critical review of neuroimaging studies. *European Psychiatry*, **2012**, 27, 181-91	6	58
341	Spatial working memory in individuals at high risk for psychosis: longitudinal fMRI study. *Schizophrenia Research*, **2010**, 123, 45-52	3.6	58
340	Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. *World Psychiatry*, **2020**, 19, 214-232	14.4	57
339	Abnormal relationship between medial temporal lobe and subcortical dopamine function in people with an ultra high risk for psychosis. *Schizophrenia Bulletin*, **2012**, 38, 1040-9	1.3	56
338	Duration of untreated psychosis and need for admission in patients who engage with mental health services in the prodromal phase. *British Journal of Psychiatry*, **2015**, 207, 130-134	5.4	54
337	Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: a critical review. *World Journal of Biological Psychiatry*, **2013**, 14, 412-31	3.8	54
336	Transdiagnostic Risk Calculator for the Automatic Detection of Individuals at Risk and the Prediction of Psychosis: Second Replication in an Independent National Health Service Trust. *Schizophrenia Bulletin*, **2019**, 45, 562-570	1.3	53
335	Integrated Mental Health Services for the Developmental Period (0 to 25 Years): A Critical Review of the Evidence. *Frontiers in Psychiatry*, **2019**, 10, 355	5	53
334	Antidepressant, antipsychotic and psychological interventions in subjects at high clinical risk for psychosis: OASIS 6-year naturalistic study. *Psychological Medicine*, **2015**, 45, 1327-39	6.9	53
333	Altered medial temporal activation related to local glutamate levels in subjects with prodromal signs of psychosis. *Biological Psychiatry*, **2011**, 69, 97-9	7.9	53
332	Clinical Validity of DSM-5 Attenuated Psychosis Syndrome: Advances in Diagnosis, Prognosis, and Treatment. *JAMA Psychiatry*, **2020**, 77, 311-320	14.5	52
331	Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis. *Lancet Psychiatry,the*, **2021**, 8, 797-812	23.3	52
330	Functional outcome in people at high risk for psychosis predicted by thalamic glutamate levels and prefronto-striatal activation. *Schizophrenia Bulletin*, **2015**, 41, 429-39	1.3	51
329	Interpersonal sensitivity in the at-risk mental state for psychosis. *Psychological Medicine*, **2012**, 42, 1835-45	4.9	50
328	Preventive Treatments for Psychosis: Umbrella Review (Just the Evidence). *Frontiers in Psychiatry*, **2019**, 10, 764	5	50
327	Evidence-based umbrella review of 162 peripheral biomarkers for major mental disorders. *Translational Psychiatry*, **2020**, 10, 152	8.6	48
326	Should attenuated psychosis syndrome be included in DSM-5?. *Lancet, The*, **2012**, 379, 591-2	40	48
325	Preventive psychiatry: a blueprint for improving the mental health of young people. *World Psychiatry*, **2021**, 20, 200-221	14.4	48

324	Predicting the onset of psychosis in patients at clinical high risk: practical guide to probabilistic prognostic reasoning. *Evidence-Based Mental Health*, **2016**, 19, 10-5	11.1	48
323	Prefrontal function at presentation directly related to clinical outcome in people at ultrahigh risk of psychosis. *Schizophrenia Bulletin*, **2011**, 37, 189-98	1.3	46
322	Depression and quality of life in patients living 10 to 18 years beyond heart transplantation. *Journal of Heart and Lung Transplantation*, **2005**, 24, 2269-78	5.8	46
321	Gray matter alterations related to P300 abnormalities in subjects at high risk for psychosis: longitudinal MRI-EEG study. *NeuroImage*, **2011**, 55, 320-8	7.9	45
320	Duration of untreated prodromal symptoms and 12-month functional outcome of individuals at risk of psychosis. *British Journal of Psychiatry*, **2009**, 194, 181-2	5.4	45
319	Imaging the neural effects of cannabinoids: current status and future opportunities for psychopharmacology. *Current Pharmaceutical Design*, **2009**, 15, 2603-14	3.3	45
318	Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 4 717 839 people. *Lancet Psychiatry,the*, **2020**, 7, 52-63	23.3	45
317	Risk factors for posttraumatic stress disorder: An umbrella review of systematic reviews and meta-analyses. *Neuroscience and Biobehavioral Reviews*, **2019**, 107, 154-165	9	44
316	Approaching a network connectivity-driven classification of the psychosis continuum: a selective review and suggestions for future research. *Frontiers in Human Neuroscience*, **2014**, 8, 1047	3.3	44
315	Evidence of reporting biases in voxel-based morphometry (VBM) studies of psychiatric and neurological disorders. *Human Brain Mapping*, **2014**, 35, 3052-65	5.9	44
314	Cannabis affects people differently: inter-subject variation in the psychotogenic effects of 9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers. *Psychological Medicine*, **2013**, 43, 1255-67	6.9	44
313	Lost in transition: setting the psychosis threshold in prodromal research. *Acta Psychiatrica Scandinavica*, **2013**, 127, 248-52	6.5	43
312	PatientsPand cliniciansPattitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis. *Therapeutic Advances in Psychopharmacology*, **2013**, 3, 89-99	4.9	43
311	Voxel-wise meta-analysis of fMRI studies in patients at clinical high risk for psychosis. *Journal of Psychiatry and Neuroscience*, **2012**, 37, 106-12	4.5	43
310	From the prodrome to chronic schizophrenia: the neurobiology underlying psychotic symptoms and cognitive impairments. *Current Pharmaceutical Design*, **2012**, 18, 459-65	3.3	43
309	Immigration, social environment and onset of psychotic disorders. *Current Pharmaceutical Design*, **2012**, 18, 518-26	3.3	43
308	Neuroimaging and electrophysiological studies of the effects of acute tryptophan depletion: a systematic review of the literature. *Psychopharmacology*, **2006**, 188, 131-43	4.7	43
307	Lithium Exposure During Pregnancy and the Postpartum Period: A Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes. *American Journal of Psychiatry*, **2020**, 177, 76-92	11.9	43

306	Insular volume abnormalities associated with different transition probabilities to psychosis. *Psychological Medicine*, **2012**, 42, 1613-25	6.9	42
305	Annual Research Review: Prevention of psychosis in adolescents - systematic review and meta-analysis of advances in detection, prognosis and intervention. *Journal of Child Psychology and Psychiatry and Allied Disciplines*, **2021**, 62, 657-673	7.9	42
304	The impact of COVID-19 lockdown on child and adolescent mental health: systematic review. *European Child and Adolescent Psychiatry*, **2021**, 1	5.5	42
303	A general approach for combining voxel-based meta-analyses conducted in different neuroimaging modalities. *Current Medicinal Chemistry*, **2013**, 20, 462-6	4.3	41
302	Using neuroimaging to help predict the onset of psychosis. *NeuroImage*, **2017**, 145, 209-217	7.9	40
301	White matter alterations related to P300 abnormalities in individuals at high risk for psychosis: an MRI-EEG study. *Journal of Psychiatry and Neuroscience*, **2011**, 36, 239-48	4.5	40
300	What is good mental health? A scoping review. *European Neuropsychopharmacology*, **2020**, 31, 33-46	1.2	40
299	Extending the Benefits of Indicated Prevention to Improve Outcomes of First-Episode Psychosis. *JAMA Psychiatry*, **2017**, 74, 667-668	14.5	39
298	Predictors of functional outcome in individuals at high clinical risk for psychosis at six years follow-up. *Journal of Psychiatric Research*, **2015**, 65, 115-23	5.2	39
297	Long-acting injectable antipsychotics in early psychosis: a literature review. *Microbial Biotechnology*, **2013**, 7, 247-54	3.3	39
296	Determinants of quality of life in Marfan syndrome. *Psychosomatics*, **2008**, 49, 243-8	2.6	39
295	Neuroimaging studies of the early stages of psychosis: a critical review. *European Psychiatry*, **2008**, 23, 237-44	6	39
294	What Is an Attenuated Psychotic Symptom? On the Importance of the Context. *Schizophrenia Bulletin*, **2017**, 43, 687-692	1.3	39
293	Modulation of motivational salience processing during the early stages of psychosis. *Schizophrenia Research*, **2015**, 166, 17-23	3.6	38
292	Neural correlates of visuospatial working memory in the at-risk mental state? *Psychological Medicine*, **2010**, 40, 1987-99	6.9	38
291	Effects of acute antipsychotic treatment on brain activation in first episode psychosis: an fMRI study. *European Neuropsychopharmacology*, **2007**, 17, 492-500	1.2	38
290	Services for people at high risk improve outcomes in patients with first episode psychosis. *Acta Psychiatrica Scandinavica*, **2016**, 133, 76-85	6.5	38
289	Bullying victimisation and paranoid ideation in people at ultra high risk for psychosis. *Schizophrenia Research*, **2015**, 168, 68-73	3.6	37

288	Gray matters!--mapping the transition to psychosis. *Schizophrenia Research*, **2011**, 133, 63-7	3.6	37
287	Implementing Precision Psychiatry: A Systematic Review of Individualized Prediction Models for Clinical Practice. *Schizophrenia Bulletin*, **2021**, 47, 284-297	1.3	37
286	Antipsychotic use and risk of life-threatening medical events: umbrella review of observational studies. *Acta Psychiatrica Scandinavica*, **2019**, 140, 227-243	6.5	36
285	Improving the Detection of Individuals at Clinical Risk for Psychosis in the Community, Primary and Secondary Care: An Integrated Evidence-Based Approach. *Frontiers in Psychiatry*, **2019**, 10, 774	5	36
284	Effect of acute tryptophan depletion on pre-frontal engagement. *Psychopharmacology*, **2006**, 187, 486-97	7.7	36
283	Worldwide implementation of clinical services for the prevention of psychosis: The IEPA early intervention in mental health survey. *Microbial Biotechnology*, **2020**, 14, 741-750	3.3	35
282	Neurofunctional maps of the maternal brain and the effects of oxytocin: a multimodal voxel-based meta-analysis. *Psychiatry and Clinical Neurosciences*, **2014**, 68, 733-51	6.2	35
281	Why transition risk to psychosis is not declining at the OASIS ultra high risk service: The hidden role of stable pretest risk enrichment. *Schizophrenia Research*, **2018**, 192, 385-390	3.6	34
280	Towards Precision Medicine in Psychosis: Benefits and Challenges of Multimodal Multicenter Studies-PSYSCAN: Translating Neuroimaging Findings From Research into Clinical Practice. *Schizophrenia Bulletin*, **2020**, 46, 432-441	1.3	34
279	Why ultra high risk criteria for psychosis prediction do not work well outside clinical samples and what to do about it. *World Psychiatry*, **2017**, 16, 212-213	14.4	33
278	Forty years of structural imaging in psychosis: promises and truth. *Acta Psychiatrica Scandinavica*, **2016**, 134, 207-24	6.5	33
277	Multimodal functional and structural imaging investigations in psychosis research. *European Archives of Psychiatry and Clinical Neuroscience*, **2012**, 262 Suppl 2, S97-106	5.1	33
276	Gray matter volumetric abnormalities associated with the onset of psychosis. *Frontiers in Psychiatry*, **2012**, 3, 101	5	33
275	Anterior cingulate pathology in the prodromal stage of schizophrenia. *NeuroImage*, **2008**, 39, 553-4	7.9	33
274	Paul Eugen Bleuler and the birth of schizophrenia (1908). *American Journal of Psychiatry*, **2008**, 165, 1407	11.9	33
273	Altered activation and connectivity in a hippocampal-basal ganglia-midbrain circuit during salience processing in subjects at ultra high risk for psychosis. *Translational Psychiatry*, **2017**, 7, e1245	8.6	32
272	Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence. *European Archives of Psychiatry and Clinical Neuroscience*, **2013**, 263, 3-13	5.1	32
271	Abnormal effective connectivity and psychopathological symptoms in the psychosis high-risk state. *Journal of Psychiatry and Neuroscience*, **2014**, 39, 239-48	4.5	32

270	Glutamate and psychosis risk. *Current Pharmaceutical Design*, **2012**, 18, 466-78	3.3	32
269	Can we detect psychotic-like experiences in the general population?. *Current Pharmaceutical Design* , **2012**, 18, 376-85	3.3	32
268	Diagnostic validity of ICD-10 acute and transient psychotic disorders and DSM-5 brief psychotic disorder. *European Psychiatry*, **2017**, 45, 104-113	6	31
267	Neurobiological Models of Self-Disorders in Early Schizophrenia. *Schizophrenia Bulletin*, **2016**, 42, 874-80	1.3	31
266	Are we really mapping psychosis risk? Neuroanatomical signature of affective disorders in subjects at ultra high risk. *Psychological Medicine*, **2014**, 44, 3491-501	6.9	31
265	Structural Network Disorganization in Subjects at Clinical High Risk for Psychosis. *Schizophrenia Bulletin*, **2017**, 43, 583-591	1.3	31
264	Identifying children and adolescents at ultra high risk of psychosis in Italian neuropsychiatry services: a feasibility study. *European Child and Adolescent Psychiatry*, **2016**, 25, 91-106	5.5	30
263	A General Approach for Combining Voxel-Based Meta-Analyses Conducted in Different Neuroimaging Modalities. *Current Medicinal Chemistry*, **2013**, 20, 462-466	4.3	30
262	Probability of Transition to Psychosis in Individuals at Clinical High Risk: An Updated Meta-analysis. *JAMA Psychiatry*, **2021**, 78, 970-978	14.5	30
261	Real World Implementation of a Transdiagnostic Risk Calculator for the Automatic Detection of Individuals at Risk of Psychosis in Clinical Routine: Study Protocol. *Frontiers in Psychiatry*, **2019**, 10, 109	5	29
260	Meta-analytical prognostic accuracy of the Comprehensive Assessment of at Risk Mental States (CAARMS): The need for refined prediction. *European Psychiatry*, **2018**, 49, 62-68	6	29
259	Relationship between gyrification and functional connectivity of the prefrontal cortex in subjects at high genetic risk of schizophrenia. *Current Pharmaceutical Design*, **2012**, 18, 434-42	3.3	29
258	Modulation of neural response to happy and sad faces by acute tryptophan depletion. *Psychopharmacology*, **2007**, 193, 31-44	4.7	29
257	Psychosis Polyrisk Score (PPS) for the Detection of Individuals At-Risk and the Prediction of Their Outcomes. *Frontiers in Psychiatry*, **2019**, 10, 174	5	28
256	Functional brain networks before the onset of psychosis: A prospective fMRI study with graph theoretical analysis. *NeuroImage: Clinical*, **2012**, 1, 91-8	5.3	28
255	Severe mental illness and European COVID-19 vaccination strategies. *Lancet Psychiatry,the*, **2021**, 8, 356-359	28.9	28
254	The relationship of developmental changes in white matter to the onset of psychosis. *Current Pharmaceutical Design*, **2012**, 18, 422-33	3.3	26
253	Genetic vulnerability to affective psychopathology in childhood: a combined voxel-based morphometry and functional magnetic resonance imaging study. *Biological Psychiatry*, **2009**, 66, 231-7	7.9	26

252	Depression after lung transplantation: causes and treatment. *Lung*, **2007**, 185, 55-65	2.9	26
251	Longitudinal alterations in motivational salience processing in ultra-high-risk subjects for psychosis. *Psychological Medicine*, **2017**, 47, 243-254	6.9	25
250	Unmet needs in patients with brief psychotic disorders: Too ill for clinical high risk services and not ill enough for first episode services. *European Psychiatry*, **2019**, 57, 26-32	6	25
249	Gamma band oscillations in the early phase of psychosis: A systematic review. *Neuroscience and Biobehavioral Reviews*, **2018**, 90, 381-399	9	25
248	Environmental risk factors, protective factors, and peripheral biomarkers for ADHD: an umbrella review. *Lancet Psychiatry,the*, **2020**, 7, 955-970	23.3	25
247	Universal and selective interventions to promote good mental health in young people: Systematic review and meta-analysis. *European Neuropsychopharmacology*, **2020**, 41, 28-39	1.2	25
246	Long term outcomes of acute and transient psychotic disorders: The missed opportunity of preventive interventions. *European Psychiatry*, **2018**, 52, 126-133	6	25
245	Neurocognitive Functioning in Individuals at Clinical High Risk for Psychosis: A Systematic Review and Meta-analysis. *JAMA Psychiatry*, **2021**,	14.5	25
244	Intensive community outreach for those at ultra high risk of psychosis: dilution, not solution. *Lancet Psychiatry,the*, **2016**, 3, 18	23.3	24
243	Orbitofrontal response to drug-related stimuli after heroin administration. *Addiction Biology*, **2015**, 20, 570-9	4.6	24
242	Cognitive remediation in the early course of schizophrenia: a critical review. *Current Pharmaceutical Design*, **2012**, 18, 534-41	3.3	24
241	Polyunsaturated fatty acids in emerging psychosis: a safer alternative?. *Microbial Biotechnology*, **2014**, 8, 199-208	3.3	23
240	Anti-depressive therapies after heart transplantation. *Journal of Heart and Lung Transplantation*, **2006**, 25, 785-93	5.8	23
239	Dysfunctional insular connectivity during reward prediction in patients with first-episode psychosis. *Journal of Psychiatry and Neuroscience*, **2016**, 41, 367-376	4.5	23
238	European college of neuropsychopharmacology network on the prevention of mental disorders and mental health promotion (ECNP PMD-MHP). *European Neuropsychopharmacology*, **2019**, 29, 1301-1311	1.2	22
237	Semistructured Interview for Bipolar At Risk States (SIBARS). *Psychiatry Research*, **2018**, 264, 302-309	9.9	22
236	Diagnostic and Prognostic Significance of DSM-5 Attenuated Psychosis Syndrome in Services for Individuals at Ultra High Risk for Psychosis. *Schizophrenia Bulletin*, **2018**, 44, 264-275	1.3	21
235	Effect of image analysis software on neurofunctional activation during processing of emotional human faces. *Journal of Clinical Neuroscience*, **2010**, 17, 311-4	2.2	21

234	Risk and protective factors for mental disorders beyond genetics: an evidence-based atlas. *World Psychiatry*, **2021**, 20, 417-436	14.4	21
233	Establishing a clinical service to prevent psychosis: What, how and when? Systematic review. *Translational Psychiatry*, **2021**, 11, 43	8.6	21
232	Brain Diffusion Changes in Emerging Psychosis and the Impact of State-Dependent Psychopathology. *NeuroSignals*, **2015**, 23, 71-83	1.9	20
231	Episodic memory dysfunction in individuals at high-risk of psychosis: a systematic review of neuropsychological and neurofunctional studies. *Current Pharmaceutical Design*, **2012**, 18, 443-58	3.3	20
230	Integrating the negative psychotic symptoms in the high risk criteria for the prediction of psychosis. *Medical Hypotheses*, **2007**, 69, 959-60	3.8	20
229	Learning from COVID-19 pandemic in northen italy: Impact on mental health and clinical care. *Journal of Affective Disorders*, **2020**, 275, 78-79	6.6	19
228	TRANSD recommendations: improving transdiagnostic research in psychiatry. *World Psychiatry*, **2019**, 18, 361-362	14.4	19
227	Age-related brain structural alterations as an intermediate phenotype of psychosis. *Journal of Psychiatry and Neuroscience*, **2017**, 42, 307-319	4.5	19
226	Economic impact of early detection and early intervention of psychosis. *Current Pharmaceutical Design*, **2012**, 18, 592-5	3.3	19
225	The ultra high risk approach to define psychosis risk. *Current Pharmaceutical Design*, **2012**, 18, 346-50	3.3	19
224	Unmet needs for treatment in 102 individuals with brief and limited intermittent psychotic symptoms (BLIPS): implications for current clinical recommendations. *Epidemiology and Psychiatric Sciences*, **2019**, 29, e67	5.1	19
223	Meta-analysis of Voxel-Based Neuroimaging Studies using Seed-based d Mapping with Permutation of Subject Images (SDM-PSI). *Journal of Visualized Experiments*, **2019**,	1.6	19
222	Real-world implementation of precision psychiatry: Transdiagnostic risk calculator for the automatic detection of individuals at-risk of psychosis. *Schizophrenia Research*, **2021**, 227, 52-60	3.6	19
221	Individualized Prediction of Transition to Psychosis in 1,676 Individuals at Clinical High Risk: Development and Validation of a Multivariable Prediction Model Based on Individual Patient Data Meta-Analysis. *Frontiers in Psychiatry*, **2019**, 10, 345	5	18
220	Lifestyles and cardiovascular risk in individuals with functional psychoses. *Perspectives in Psychiatric Care*, **2009**, 45, 87-99	2.2	18
219	Potential therapeutical effects of cannabidiol in children with pharmacoresistant epilepsy. *Medical Hypotheses*, **2007**, 68, 920-1	3.8	18
218	Conceptual issues in psychiatric neuroimaging. *Current Opinion in Psychiatry*, **2006**, 19, 608-12	4.9	18
217	Oxytocin modulates hippocampal perfusion in people at clinical high risk for psychosis. *Neuropsychopharmacology*, **2019**, 44, 1300-1309	8.7	17

216	Dynamic ElecTronic hEalth reCord deTection (DETECT) of individuals at risk of a first episode of psychosis: a case-control development and validation study. *The Lancet Digital Health*, **2020**, 2, e229-e239	14.4	17
215	Clinical-learning versus machine-learning for transdiagnostic prediction of psychosis onset in individuals at-risk. *Translational Psychiatry*, **2019**, 9, 259	8.6	17
214	Medial frontal gyrus alterations in schizophrenia: relationship with duration of illness and executive dysfunction. *Psychiatry Research - Neuroimaging*, **2015**, 231, 103-10	2.9	17
213	Neural correlates of movement generation in the ʻat-risk mental stateʼ. *Acta Psychiatrica Scandinavica*, **2010**, 122, 295-301	6.5	17
212	Cingulate volume abnormalities in emerging psychosis. *Current Pharmaceutical Design*, **2012**, 18, 495-504	3.3	17
211	Association of Structural Magnetic Resonance Imaging Measures With Psychosis Onset in Individuals at Clinical High Risk for Developing Psychosis: An ENIGMA Working Group Mega-analysis. *JAMA Psychiatry*, **2021**, 78, 753-766	14.5	17
210	Pan-London Network for Psychosis-Prevention (PNP). *Frontiers in Psychiatry*, **2019**, 10, 707	5	17
209	Risk and protective factors for anxiety and obsessive-compulsive disorders: an umbrella review of systematic reviews and meta-analyses. *Psychological Medicine*, **2020**, 50, 1300-1315	6.9	17
208	Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit. *Schizophrenia Research*, **2021**, 227, 10-17	3.6	17
207	A systematic review and meta-analysis of mental health service use in people who report psychotic experiences. *Microbial Biotechnology*, **2018**, 12, 275-285	3.3	17
206	The Hype Cycle of the Clinical High Risk State for Psychosis: The Need of a Refined Approach. *Schizophrenia Bulletin*, **2018**, 44, 250-253	1.3	16
205	Striatal molecular alterations in HD gene carriers: a systematic review and meta-analysis of PET studies. *Journal of Neurology, Neurosurgery and Psychiatry*, **2018**, 89, 185-196	5.5	16
204	Getting old with a new heart: impact of age on depression and quality of life in long-term heart transplant recipients. *Journal of Heart and Lung Transplantation*, **2007**, 26, 544-8	5.8	16
203	Risk factors for eating disorders: an umbrella review of published meta-analyses. *Revista Brasileira De Psiquiatria*, **2021**, 43, 314-323	2.6	16
202	Transdiagnostic Individualized Clinically Based Risk Calculator for the Detection of Individuals at Risk and the Prediction of Psychosis: Model Refinement Including Nonlinear Effects of Age. *Frontiers in Psychiatry*, **2019**, 10, 313	5	15
201	Polyunsaturated fatty acids in emerging psychosis. *Current Pharmaceutical Design*, **2012**, 18, 576-91	3.3	15
200	ʻTrumanʼ signs and vulnerability to psychosis. *British Journal of Psychiatry*, **2008**, 193, 168	5.4	15
199	Olfactory and gustatory dysfunctions in SARS-CoV-2 infection: A systematic review. *Brain, Behavior, & Immunity - Health*, **2021**, 15, 100268	5.1	15

198	Real-world long-term outcomes in individuals at clinical risk for psychosis: The case for extending duration of care. *EClinicalMedicine*, **2020**, 28, 100578	11.3	14
197	Using Natural Language Processing on Electronic Health Records to Enhance Detection and Prediction of Psychosis Risk. *Schizophrenia Bulletin*, **2021**, 47, 405-414	1.3	14
196	Superior temporal gray and white matter changes in schizophrenia or antipsychotic related effects?. *Schizophrenia Research*, **2009**, 113, 109-10	3.6	13
195	A Case of a College Student Presenting With Mild Mental Health Problems. *JAMA Psychiatry*, **2018**, 75, 1298-1299	14.5	13
194	Dysbindin modulates brain function during visual processing in children. *NeuroImage*, **2010**, 49, 817-22	7.9	12
193	The effects of antipsychotics on brain structure: what have we learnt from structural imaging of schizophrenia?. *Psychological Medicine*, **2009**, 39, 1781-2	6.9	12
192	Reliability and validity of the Comprehensive Assessment of the At Risk Mental State, Italian version (CAARMS-I). *Current Pharmaceutical Design*, **2012**, 18, 386-91	3.3	12
191	Outreach and support in South-London (OASIS) 2001-2020: Twenty years of early detection, prognosis and preventive care for young people at risk of psychosis. *European Neuropsychopharmacology*, **2020**, 39, 111-122	1.2	12
190	Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review. *World Psychiatry*, **2021**, 20, 244-275	14.4	12
189	Peripheral levels of C-reactive protein, tumor necrosis factor-⍺interleukin-6, and interleukin-1⍺ across the mood spectrum in bipolar disorder: A meta-analysis of mean differences and variability. *Brain, Behavior, and Immunity*, **2021**, 97, 193-203	16.6	12
188	Formal thought disorder in people at ultra-high risk of psychosis. *BJPsych Open*, **2017**, 3, 165-170	5	11
187	White matter pathology--an endophenotype for bipolar disorder?. *BMC Psychiatry*, **2012**, 12, 138	4.2	11
186	Neuroimaging and resilience factors--staging of the at-risk mental state?. *Current Pharmaceutical Design*, **2012**, 18, 416-21	3.3	11
185	Viewpoint	European COVID-19 exit strategy for people with severe mental disorders: Too little, but not yet too late. *Brain, Behavior, and Immunity*, **2021**, 94, 15-17	16.6	11
184	Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack. *Journal of Visualized Experiments*, **2020**,	1.6	10
183	Neighbourhood deprivation is positively associated with detection of the ultra-high risk (UHR) state for psychosis in South East London. *Schizophrenia Research*, **2018**, 192, 371-376	3.6	10
182	Development and Validation of a Dynamic Risk Prediction Model to Forecast Psychosis Onset in Patients at Clinical High Risk. *Schizophrenia Bulletin*, **2020**, 46, 252-260	1.3	10
181	Second Life virtual world: a heaven for autistic people?. *Medical Hypotheses*, **2008**, 71, 980-1	3.8	10

180	Association between mental disorders and somatic conditions: protocol for an umbrella review. *Evidence-Based Mental Health*, **2020**, 23, 135-139	11.1	10
179	The gut-microbiome as a target for the treatment of schizophrenia: A systematic review and meta-analysis of randomised controlled trials of add-on strategies. *Schizophrenia Research*, **2021**, 234, 1-13	3.6	10
178	Prevalence and implications of Truman symptoms in subjects at ultra high risk for psychosis. *Psychiatry Research*, **2016**, 238, 270-276	9.9	9
177	Sensory gating deficits in the attenuated psychosis syndrome. *Schizophrenia Research*, **2015**, 161, 277-82	3.6	9
176	Predictive power of attenuated psychosis syndrome: is it really low? The case of mild cognitive impairment. *Schizophrenia Research*, **2012**, 135, 192-3	3.6	9
175	Franco Basaglia (1924--1980): three decades (1979--2009) as a bridge between the Italian and Brazilian mental health reform. *International Journal of Social Psychiatry*, **2011**, 57, 100-3	8.5	9
174	Effects of antipsychotics on dentate gyrus stem cell proliferation and survival in animal models: a critical update. *Neural Plasticity*, **2012**, 2012, 832757	3.3	9
173	Genetic vulnerability to psychosis and cortical function: epistatic effects between DAAO and G72. *Current Pharmaceutical Design*, **2012**, 18, 510-7	3.3	9
172	Ethical implications for clinical practice and future research in "at risk" individuals. *Current Pharmaceutical Design*, **2012**, 18, 606-12	3.3	9
171	Neurophysiological response to emotional faces with increasing intensity of fear: a skin conductance response study. *Journal of Clinical Neuroscience*, **2009**, 16, 981-2	2.2	9
170	A large scale meta-analytic atlas of mental health problems prevalence during the COVID-19 early pandemic.. *Journal of Medical Virology*, **2021**,	19.7	9
169	E-Clinical High Risk for Psychosis: Viewpoint on Potential of Digital Innovations for Preventive Psychiatry. *JMIR Mental Health*, **2019**, 6, e14581	6	9
168	Real-World Clinical Outcomes Two Years After Transition to Psychosis in Individuals at Clinical High Risk: Electronic Health Record Cohort Study. *Schizophrenia Bulletin*, **2020**,	1.3	9
167	Suicide, self-harm and thoughts of suicide or self-harm in infectious disease epidemics: a systematic review and meta-analysis. *Epidemiology and Psychiatric Sciences*, **2021**, 30, e32	5.1	9
166	Negative Psychosis Prevention Trials. *JAMA Psychiatry*, **2017**, 74, 651	14.5	8
165	An initial investigation of abnormal bodily phenomena in subjects at ultra high risk for psychosis: Their prevalence and clinical implications. *Comprehensive Psychiatry*, **2016**, 66, 39-45	7.3	8
164	The impact of delivering GP training on the clinical high risk and first-episode psychosis on referrals and pathways to care. *Microbial Biotechnology*, **2015**, 9, 459-66	3.3	8
163	Longitudinal outcome of attenuated positive symptoms, negative symptoms, functioning and remission in people at clinical high risk for psychosis: a meta-analysis. *EClinicalMedicine*, **2021**, 36, 100909	11.3	8

162	Toward Generalizable and Transdiagnostic Tools for Psychosis Prediction: An Independent Validation and Improvement of the NAPLS-2 Risk Calculator in the Multisite PRONIA Cohort. *Biological Psychiatry*, **2021**, 90, 632-642	7.9	8
161	The relationship between ethnicity and service access, treatment uptake and the incidence of psychosis among people at ultra high risk for psychosis. *Psychiatry Research*, **2019**, 272, 618-627	9.9	8
160	Disparities in Screening and Treatment of Cardiovascular Diseases in Patients With Mental Disorders Across the World: Systematic Review and Meta-Analysis of 47 Observational Studies. *American Journal of Psychiatry*, **2021**, 178, 793-803	11.9	8
159	Primary prevention of depression: An umbrella review of controlled interventions. *Journal of Affective Disorders*, **2021**, 294, 957-970	6.6	8
158	Short clinically-based prediction model to forecast transition to psychosis in individuals at clinical high risk state. *European Psychiatry*, **2019**, 58, 72-79	6	7
157	Hippocampal volume correlates with attenuated negative psychotic symptoms irrespective of antidepressant medication. *NeuroImage: Clinical*, **2015**, 8, 230-7	5.3	7
156	Basic Self-Disturbances Related to Reduced Anterior Cingulate Volume in Subjects at Ultra-High Risk for Psychosis. *Frontiers in Psychiatry*, **2019**, 10, 254	5	7
155	Pattern of activation during delayed matching to sample task predicts functional outcome in people at ultra high risk for psychosis. *Schizophrenia Research*, **2017**, 181, 86-93	3.6	7
154	Neuropsychopharmacology of auditory hallucinations: insights from pharmacological functional MRI and perspectives for future research. *Expert Review of Neurotherapeutics*, **2013**, 13, 23-36	4.3	7
153	The vulnerability to schizophrenia mainstream research paradigms and phenomenological directions. *Current Pharmaceutical Design*, **2012**, 18, 338-45	3.3	7
152	Egas Moniz (1875-1955), the father of psychosurgery. *British Journal of Psychiatry*, **2008**, 193, 50	5.4	7
151	Aripiprazole monotherapy as transdiagnostic intervention for the treatment of mental disorders: An umbrella review according to TRANSD criteria. *European Neuropsychopharmacology*, **2020**, 41, 16-27	1.2	7
150	Transdiagnostic individualized clinically-based risk calculator for the automatic detection of individuals at-risk and the prediction of psychosis: external replication in 2,430,333 US patients. *Translational Psychiatry*, **2020**, 10, 364	8.6	7
149	Lower speech connectedness linked to incidence of psychosis in people at clinical high risk. *Schizophrenia Research*, **2021**, 228, 493-501	3.6	7
148	Association of antidepressants with brain morphology in early stages of psychosis: an imaging genomics approach. *Scientific Reports*, **2019**, 9, 8516	4.9	6
147	Towards a framework for good outcome in people at clinical high risk for psychosis: A Delphi consensus study. *Schizophrenia Research*, **2019**, 208, 209-216	3.6	6
146	Impact on the Onset of Psychosis of a Polygenic Schizophrenia-Related Risk Score and Changes in White Matter Volume. *Cellular Physiology and Biochemistry*, **2018**, 48, 1201-1214	3.9	6
145	People meeting ultra high risk for psychosis criteria in the community. *World Psychiatry*, **2017**, 16, 322-323	34.4	6

144	Why is psychiatric imaging clinically unreliable? Epistemological perspectives in clinical neuroscience. *Psychotherapy and Psychosomatics*, **2009**, 78, 320-1	9.4	6
143	Johann Cristian Reil on the 200th anniversary of the first description of the insula (1809). *Journal of Neurology, Neurosurgery and Psychiatry*, **2009**, 80, 1409	5.5	6
142	Neurophysiological alterations in the prepsychotic phases. *Current Pharmaceutical Design*, **2012**, 18, 479-85	3.5	6
141	Philosophical issues in the prodromal phase of psychosis. *Current Pharmaceutical Design*, **2012**, 18, 596-605	3.5	6
140	Abnormal thalamic glutamate and liability to psychosis: state or trait marker?. *Schizophrenia Research*, **2009**, 115, 94-5	3.6	6
139	Franco Basaglia, 1924-1980. *American Journal of Psychiatry*, **2008**, 165, 968	11.9	6
138	Association between autism spectrum disorder and inflammatory bowel disease: A systematic review and meta-analysis.. *Autism Research*, **2021**,	5.1	6
137	Psychiatric and neuropsychiatric syndromes and COVID-19 - Authors'reply. *Lancet Psychiatry,the*, **2020**, 7, 664-665	23.3	6
136	Real-world digital implementation of the Psychosis Polyrisk Score (PPS): A pilot feasibility study. *Schizophrenia Research*, **2020**, 226, 176-183	3.6	6
135	Gender differences in clinical presentation and illicit substance use during first episode psychosis: a natural language processing, electronic case register study. *BMJ Open*, **2021**, 11, e042949	3	6
134	Risk and protective factors for mental disorders with onset in childhood/adolescence: An umbrella review of published meta-analyses of observational longitudinal studies. *Neuroscience and Biobehavioral Reviews*, **2021**, 120, 565-573	9	6
133	One century of Allgemeine Psychopathologie (1913 to 2013) by Karl Jaspers. *Schizophrenia Bulletin*, **2013**, 39, 268-9	1.3	5
132	Marfan syndrome and liability to psychosis. *Medical Hypotheses*, **2007**, 68, 1173-4	3.8	5
131	Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials.. *JAMA Psychiatry*, **2022**,	14.5	5
130	Methodological Biases in CBT Trial-Commentary: Modular Cognitive-Behavioral Therapy for Affective Symptoms in Young Individuals at Ultra-High Risk of First Episode of Psychosis: Randomized Controlled Trial. *Frontiers in Psychiatry*, **2020**, 11, 394	5	5
129	Universal and Selective Interventions to Prevent Poor Mental Health Outcomes in Young People: Systematic Review and Meta-analysis. *Harvard Review of Psychiatry*, **2021**, 29, 196-215	4.1	5
128	The prevalence, odds and predictors of lifespan comorbid eating disorder among people with a primary diagnosis of bipolar disorders, and vice-versa: Systematic review and meta-analysis. *Journal of Affective Disorders*, **2021**, 280, 409-431	6.6	5
127	Psychotic experiences, psychiatric comorbidity and mental health need in the general population: a cross-sectional and cohort study in Southeast London. *Psychological Medicine*, **2021**, 51, 147-157	6.9	5

126	Third external replication of an individualised transdiagnostic prediction model for the automatic detection of individuals at risk of psychosis using electronic health records. *Schizophrenia Research*, **2021**, 228, 403-409	3.6	5
125	Neurochemical effects of oxytocin in people at clinical high risk for psychosis. *European Neuropsychopharmacology*, **2019**, 29, 601-615	1.2	4
124	World/self ambivalence: A shared mechanism in different subsets of psychotic experiences? Linking symptoms with resting-state fMRI. *Psychiatry Research - Neuroimaging*, **2020**, 299, 111068	2.9	4
123	The Provision of Education and Employment Support At the Outreach and Support in South London (OASIS) Service for People at Clinical High Risk for Psychosis. *Frontiers in Psychiatry*, **2019**, 10, 799	5	4
122	Julius Wagner-Jauregg, 1857-1940. *American Journal of Psychiatry*, **2009**, 166, 409	11.9	4
121	Predicting the development of schizophrenia. *British Journal of Psychiatry*, **2012**, 200, 254-5; author reply 255	5.4	4
120	Cannabis abuse and vulnerability to psychosis: targeting preventive services. *Current Pharmaceutical Design*, **2012**, 18, 542-9	3.3	4
119	Multimodal functional imaging investigation before and after the onset of psychosis. *International Journal of Neuropsychopharmacology*, **2009**, 12, 579-81	5.8	4
118	Heterogeneity in the assessment of the at-risk mental state for psychosis. *Psychiatric Services*, **2008**, 59, 813	3.3	4
117	Prevalence of Individuals at Clinical High-Risk of Psychosis in the General Population and Clinical Samples: Systematic Review and Meta-Analysis. *Brain Sciences*, **2021**, 11,	3.4	4
116	Longitudinal Course of Depressive, Anxiety, and Posttraumatic Stress Disorder Symptoms After Heart Surgery: A Meta-Analysis of 94 Studies. *Psychosomatic Medicine*, **2021**, 83, 85-93	3.7	4
115	Proportion of young people in the general population consulting general practitioners: Potential for mental health screening and prevention. *Microbial Biotechnology*, **2020**, 14, 631-635	3.3	4
114	Intranasal oxytocin increases heart-rate variability in men at clinical high risk for psychosis: a proof-of-concept study. *Translational Psychiatry*, **2020**, 10, 227	8.6	4
113	Prognostic Accuracy of DSM-5 Attenuated Psychosis Syndrome in Adolescents: Prospective Real-World 5-Year Cohort Study. *Schizophrenia Bulletin*, **2021**, 47, 1663-1673	1.3	4
112	Evaluation of variability in individual response to treatments in the clinical high-risk state for psychosis: A meta-analysis. *Schizophrenia Research*, **2021**, 227, 20-27	3.6	4
111	Associations between mental and physical conditions in children and adolescents: An umbrella review.. *Neuroscience and Biobehavioral Reviews*, **2022**, 137, 104662	9	4
110	Mind the translation gap: problems in the implementation of early intervention services. *Psychological Medicine*, **2010**, 40, 171-2	6.9	3
109	Maurice Merleau-Ponty and the "embodied subjectivity" (1908-61). *Medical Anthropology Quarterly*, **2009**, 23, 91-3	2.5	3

108	Biochemical markers of impending psychosis. *Current Pharmaceutical Design*, **2012**, 18, 505-9	3.3	3
107	Medicine and the arts. Brain Damage by Pink Floyd (1973). Commentary. *Academic Medicine*, **2008**, 83, 742-3	3.9	3
106	Love and brain: from mereological fallacy to "folk" neuroimaging. *Psychiatry Research - Neuroimaging*, **2007**, 154, 285-6	2.9	3
105	Insular pathology in the at-risk mental state. *European Archives of Psychiatry and Clinical Neuroscience*, **2008**, 258, 254-5	5.1	3
104	Can acute tryptophan depletion modulate brain function in absence of behavioural effects?. *Medical Hypotheses*, **2007**, 68, 722	3.8	3
103	Linking autism, regression and Landau-Kleffner syndrome: integrative role of nerve growth factor. *Medical Hypotheses*, **2007**, 68, 1178-9	3.8	3
102	Imaging Genomics - An integrative approach to understand the biological susceptibility for schizophrenia. *Medical Hypotheses*, **2007**, 68, 1426	3.8	3
101	Quetiapine as a first-choice agent in subjects at high-risk to psychosis?. *Medical Hypotheses*, **2007**, 69, 230	3.8	3
100	Diagnosis, prognosis, and treatment of brief psychotic episodes: a review and research agenda. *Lancet Psychiatry,the*, **2021**,	23.3	3
99	Promoting good mental health in the whole population: The new frontier. *European Neuropsychopharmacology*, **2021**, 55, 8-10	1.2	3
98	T97. REAL WORLD IMPLEMENTATION OF A TRANSDIAGNOSTIC RISK CALCULATOR FOR THE AUTOMATIC DETECTION OF INDIVIDUALS AT RISK OF PSYCHOSIS IN CLINICAL ROUTINE. *Schizophrenia Bulletin*, **2020**, 46, S268-S268	1.3	3
97	DSM-5 Attenuated Psychosis Syndrome in Adolescents Hospitalized With Non-psychotic Psychiatric Disorders. *Frontiers in Psychiatry*, **2020**, 11, 568982	5	3
96	Genetic Variation and Autism: A Field Synopsis and Systematic Meta-Analysis. *Brain Sciences*, **2020**, 10,	3.4	3
95	Early intervention in psychosis during the COVID-19 pandemic: Maudsley recommendations. *European Neuropsychopharmacology*, **2021**, 47, 130-135	1.2	3
94	Examining service-user perspectives for the development of a good outcome checklist for individuals at clinical high risk for psychosis. *Microbial Biotechnology*, **2021**, 15, 606-615	3.3	3
93	Risk and protective factors for cannabis, cocaine, and opioid use disorders: An umbrella review of meta-analyses of observational studies. *Neuroscience and Biobehavioral Reviews*, **2021**, 126, 243-251	9	3
92	Risk and Protective Factors for Personality Disorders: An Umbrella Review of Published Meta-Analyses of Case-Control and Cohort Studies. *Frontiers in Psychiatry*, **2021**, 12, 679379	5	3
91	Development of a probability calculator for psychosis risk in children, adolescents, and young adults. *Psychological Medicine*, **2021**, 1-9	6.9	3

90	The lived experience of psychosis: a bottom-up review co-written by experts by experience and academics.. *World Psychiatry*, **2022**, 21, 168-188	14.4	3
89	Acute oxytocin effects in inferring othersʔbeliefs and social emotions in people at clinical high risk for psychosis. *Translational Psychiatry*, **2020**, 10, 203	8.6	2
88	Gray matter pathology of hippocampus - a specific endophenotype for schizophrenia?. *Psychiatry Research - Neuroimaging*, **2012**, 202, 273-4	2.9	2
87	A General Approach for Combining Voxel-Based Meta-Analyses Conducted in Different Neuroimaging Modalities. *Current Medicinal Chemistry*, **2013**, 20, 462-466	4.3	2
86	Response to Spencer et al. Letter. *American Journal of Psychiatry*, **2012**, 169, 666-666	11.9	2
85	Distinct Effects of D9-tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing. *European Psychiatry*, **2009**, 24, 1-1	6	2
84	From Brentano to mirror neurons: bridging phenomenology and clinical neuroscience. *Psychiatry Research - Neuroimaging*, **2010**, 183, 245-6	2.9	2
83	Roger Keith "Syd" Barrett (1946-2006). *American Journal of Psychiatry*, **2007**, 164, 1028	11.9	2
82	Medicine and the arts. Two allegories of love by Agnolo di Cosimo di Mariano "Bronzino" and Bartels, et al. Commentary. *Academic Medicine*, **2007**, 82, 1108-9	3.9	2
81	Can neuroimaging reduce social stigma in schizophrenia?. *Medical Hypotheses*, **2007**, 69, 457	3.8	2
80	Pooling of data in psychiatric neuroimaging: a bridge towards clinical neuroimaging?. *European Psychiatry*, **2007**, 22, 265	6	2
79	Proportion and predictors of remission and recovery in first-episode psychosis: Systematic review and meta-analysis. *European Psychiatry*, **2021**, 64, e69	6	2
78	Transcriptional biomarkers of response to pharmacological treatments in severe mental disorders: A systematic review.. *European Neuropsychopharmacology*, **2022**, 55, 112-157	1.2	2
77	Psychosocial Intervention Without Antipsychotic Medication for Brief Psychotic Episodes?. *Schizophrenia Bulletin Open*, **2020**, 1,	2.2	2
76	Early Intervention Services for First Episode of Psychosis in South London and the Maudsley (SLaM): 20 Years of Care and Research for Young People. *Frontiers in Psychiatry*, **2020**, 11, 577110	5	2
75	The Collaborative Outcomes study on Health and Functioning during Infection Times in Adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic.. *Journal of Affective Disorders*, **2021**, 299, 393-393	6.6	2
74	Prison and Community Populations at Ultra-High Risk of Psychosis: Differences and Challenges for Service Provision. *Psychiatric Services*, **2016**, 67, 990-5	3.3	2
73	Risk and protective factors for alcohol and tobacco related disorders: An umbrella review of observational studies. *Neuroscience and Biobehavioral Reviews*, **2021**, 121, 20-28	9	2

72	Suicide, self-harm and thoughts of suicide or self-harm in infectious disease epidemics: a systematic review and meta-analysis CORRIGENDUM. *Epidemiology and Psychiatric Sciences*, **2021**, 30,	5.1	2
71	Impact of Comorbid Affective Disorders on Longitudinal Clinical Outcomes in Individuals at Ultra-high Risk for Psychosis. *Schizophrenia Bulletin*, **2021**,	1.3	2
70	Lack of robust meta-analytic evidence to favour cognitive behavioural therapy for prevention of psychosis. *World Psychiatry*, **2021**, 20, 443-444	14.4	2
69	Clinical prediction models in psychiatry: a systematic review of two decades of progress and challenges.. *Molecular Psychiatry*, **2022**,	15.1	2
68	Neuroimaging and the At-Risk Mental State **2019**, 219-265		1
67	The Psychosis High-Risk State. *Key Issues in Mental Health*,55-68		1
66	Bupropion and panic disorder: case report and review of the literature. *Journal of Neuropsychiatry and Clinical Neurosciences*, **2011**, 23, E47-50	2.7	1
65	P.3.02 Opposite neural effects of the main psychoactive ingredients of cannabis Implications for therapeutics. *European Neuropsychopharmacology*, **2009**, 19, S63-S64	1.2	1
64	Albert Hofmann, the father of LSD (1906-2008). *Neuropsychobiology*, **2008**, 58, 53-4	4	1
63	Successful antidepressive treatment with mirtazapine following lung transplantation. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2008**, 32, 1745-6	5.5	1
62	Differential diagnosis between the early onset of schizophrenia and bipolar disorder: potential role of neuroimaging. *CNS Spectrums*, **2008**, 13, 363-4	1.8	1
61	Anxiety and depression after lung transplantation: Mirtazapine as a first-choice agent?. *Journal of Psychosomatic Research*, **2007**, 62, 101	4.1	1
60	Memantine as a neuroprotective agent in early phases of psychosis. *Medical Hypotheses*, **2007**, 68, 459-60	3.8	1
59	Uncovering the neural correlates of the ketogenic diet: the contribution of functional neuroimaging. *Medical Hypotheses*, **2007**, 69, 705-6	3.8	1
58	Targeting the effects of omega-3 and omega-6 fatty acid supplementation on schizophrenic spectrum disorders: role of neuroimaging. *Medical Hypotheses*, **2007**, 69, 466-7	3.8	1
57	Is a DNA sequence variation of the gene protocadherin Y a possible explanation for the sixfold higher risk to develop schizophrenia in Moroccan males?. *Medical Hypotheses*, **2007**, 69, 694	3.8	1
56	Focusing on Comorbidity-A Novel Meta-Analytic Approach and Protocol to Disentangle the Specific Neuroanatomy of Co-occurring Mental Disorders.. *Frontiers in Psychiatry*, **2021**, 12, 807839	5	1
55	Public health primary prevention implemented by clinical high-risk services for psychosis.. *Translational Psychiatry*, **2022**, 12, 43	8.6	1

54	Clinical outcomes in individuals at clinical high risk of psychosis who do not transition to psychosis: a meta-analysis.. *Epidemiology and Psychiatric Sciences*, **2022**, 31, e9	5.1	1
53	Overoptimistic Literature and Methodological Biases Favoring Cognitive Behavioral Therapy for the Prevention of Psychosis. *Schizophrenia Bulletin*, **2021**,	1.3	1
52	Mapping Prodromal Psychosis **2011**, 445-471		1
51	Emergency department and early detection of adolescents and young adults at risk of developing mental disorders: an exploratory study. *Research in Psychotherapy: Psychopathology, Process and Outcome*, **2020**, 23, 459	0.9	1
50	Towards standardising the assessment of good outcome in people at clinical high risk for psychosis: A collaborative approach. *Schizophrenia Research*, **2020**, 223, 361-362	3.6	1
49	Cortical gray matter reduction precedes transition to psychosis in individuals at clinical high-risk for psychosis: A voxel-based meta-analysis. *Schizophrenia Research*, **2021**, 232, 98-106	3.6	1
48	Antipsychotics and Attenuated Psychosis Syndrome: Transdiagnostic assessment and discontinuation strategies. *Schizophrenia Research*, **2021**,	3.6	1
47	A Pilot Study on Covid and Autism: Prevalence, Clinical Presentation and Vaccine Side Effects. *Brain Sciences*, **2021**, 11,	3.4	1
46	New Electronic Health Records Screening Tools to Improve Detection of Emerging Psychosis. *Frontiers in Psychiatry*, **2021**, 12, 698406	5	1
45	The case for improved transdiagnostic detection of first-episode psychosis: Electronic health record cohort study. *Schizophrenia Research*, **2021**, 228, 547-554	3.6	1
44	Can we increase the subjective well-being of the general population? An umbrella review of the evidence. *Revista De Psiquiatría Y Salud Mental*, **2021**, 14, 50-64	2.7	1
43	Transition to psychosis in randomized clinical trials of individuals at clinical high risk of psychosis compared to observational cohorts: a systematic review and meta-analysis. *European Psychiatry*, **2021**, 64, e51	6	1
42	ITAlian partnership for psychosis prevention (ITAPP): Improving the mental health of young people. *European Psychiatry*, **2021**, 64, e62	6	1
41	Structural brain volumes of individuals at clinical high risk for psychosis: a meta-analysis. *Biological Psychiatry Global Open Science*, **2021**,		1
40	Assessing psychosis risk using quantitative markers of disorganised speech		1
39	Establishing a business case for setting up early detection services for preventing psychosis.. *BJPsych Bulletin*, **2022**, 1-10	1.2	1
38	Differential expression of MicroRNAs in Alzheimer?s disease: a systematic review and meta-analysis.. *Molecular Psychiatry*, **2022**,	15.1	1
37	Higher levels of mental wellbeing predict lower risk of common mental disorders in the Danish general population. *Mental Health and Prevention*, **2022**, 26, 200233	2.3	1

36	No Meta-analytic Effect of age on Probability of Developing Psychosis in Individuals at Clinical High Risk for Psychosis.. *Journal of the American Academy of Child and Adolescent Psychiatry*, **2021**,	7.2	1
35	Identifying Electroencephalography Biomarkers in Individuals at Clinical High Risk for Psychosis in an International Multi-Site Study.. *Frontiers in Psychiatry*, **2022**, 13, 828376	5	1
34	Development of a Self-Administered Questionnaire to Detect Psychosis at High Altitude: The HAPSY Questionnaire. *High Altitude Medicine and Biology*, **2019**, 20, 352-360	1.9	0
33	Impact of data extraction errors in meta-analyses on the association between depression and peripheral inflammatory biomarkers: an umbrella review. *Psychological Medicine*, **2021**, 1-14	6.9	0
32	Developing and Validating an Individualized Clinical Prediction Model to Forecast Psychotic Recurrence in Acute and Transient Psychotic Disorders: Electronic Health Record Cohort Study. *Schizophrenia Bulletin*, **2021**, 47, 1695-1705	1.3	0
31	Early detection of bipolar disorders and treatment recommendations for help-seeking adolescents and young adults: Findings of the Early Detection and Intervention Center Dresden. *International Journal of Bipolar Disorders*, **2021**, 9, 23	5.4	0
30	A systematic review and meta-analysis of structural and functional brain alterations in individuals with genetic and clinical high-risk for psychosis and bipolar disorder.. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2022**, 110540	5.5	0
29	Relapse prevention in schizophrenia.. *Lancet Psychiatry,the*, **2022**, 9, e13	23.3	0
28	Natural Language Processing markers in first episode psychosis and people at clinical high-risk.. *Translational Psychiatry*, **2021**, 11, 630	8.6	0
27	Psychosis and Substance Abuse increase the COVID-19 mortality risk.. *Psychological Medicine*, **2022**, 1-23	6.9	0
26	Examining the variability of neurocognitive functioning in individuals at clinical high risk for psychosis: a meta-analysis.. *Translational Psychiatry*, **2022**, 12, 198	8.6	0
25	Associations of presenting symptoms and subsequent adverse clinical outcomes in people with unipolar depression: a prospective natural language processing (NLP), transdiagnostic, network analysis of electronic health record (EHR) data.. *BMJ Open*, **2022**, 12, e056541	3	0
24	Prognostic accuracy and clinical utility of psychometric instruments for individuals at clinical high-risk of psychosis: a systematic review and meta-analysis. *Molecular Psychiatry*,	15.1	0
23	Research Perspectives for Neuroimaging of Schizophrenia Spectrum Disorders **2019**, 303-325		
22	Neuroimaging and the Longitudinal Course of Schizophrenia **2019**, 183-218		
21	Specialized services for individuals at clinical high risk for psychosis target simultaneously adolescents and young adults. *International Journal of Technology Assessment in Health Care*, **2019**, 35, 408-409	1.8	
20	SSRIs and autism: interpreting an umbrella review - AuthorsPreply. *Lancet Psychiatry,the*, **2019**, 6, 893-894	23.3	
19	Presynaptic dopamine alterations in schizophrenia: functional or structural defect?. *Psychiatry Research - Neuroimaging*, **2012**, 202, 271-2	2.9	

18	Long-Chain Omega-3 Fatty Acids and Psychotic Disorders **2013**, 149-178	
17	Comment on "schizophrenia, brain disease and meta-analyses: integrating the pieces and testing Fusar-Poli's hypothesis". *Medical Hypotheses*, **2010**, 74, 395-6	3.8
16	P.3.019 A meta-analysis of neuroimaging predictors of transition to psychosis. *European Neuropsychopharmacology*, **2010**, 20, S78	1.2
15	Images in psychiatry. Sabina Spielrein. *American Journal of Psychiatry*, **2012**, 169, 21	11.9
14	Can neuroimaging prove that schizophrenia is a brain disease? A radical hypothesis. *Medical Hypotheses*, **2009**, 73, 855-6	3.8
13	Opposite Neural Effects of the Main Psychoactive Ingredients of Cannabis- Neural Basis for Potential Therapeutic Effects of Cannabidiol. *European Psychiatry*, **2009**, 24, 1-1	6
12	NEURAL CORRELATES OF VERBAL EPISODIC MEMORY IN THE AT RISK MENTAL STATE. *Schizophrenia Research*, **2008**, 102, 29-30	3.6
11	P.3.21 Delta-9-tetrahydrocannabinol modulates activity in parahippocampal cortex and ventral striatum during memory processing. *European Neuropsychopharmacology*, **2008**, 18, s80	1.2
10	P.1.e.020 Effects of cannabis ingredients in the temporal cortex – neural basis for potential antipsychotic effect of cannabidiol. *European Neuropsychopharmacology*, **2008**, 18, S270-S271	1.2
9	Socioeconomic provisions for specialist training in Italy and the UK: integrating the differences. *Postgraduate Medical Journal*, **2006**, 82, 810-2	2
8	Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe.. *Neuropsychiatric Disease and Treatment*, **2022**, 18, 201-219	3.1
7	Acute Tryptophan Depletion and Suicidality. *Journal of Psychophysiology*, **2007**, 21, 72-73	1
6	Early Intervention in Psychosis 299-306	
5	Authors' reply. *British Journal of Psychiatry*, **2016**, 208, 197-8	5.4
4	Can we increase the subjective well-being of the general population? An umbrella review of the evidence. *Revista De Psiquiatría Y Salud Mental (English Edition)*, **2021**, 14, 50-64	0.2
3	Manifesto for an ECNP Neuromodulation Thematic Working Group (TWG): Non-invasive brain stimulation as a new Super-subspecialty. *European Neuropsychopharmacology*, **2021**, 52, 72-83	1.2
2	P.0178 Transition to psychosis in adolescents at clinical high risk for psychosis: a meta-analysis. *European Neuropsychopharmacology*, **2021**, 53, S129-S130	1.2
1	Perceived Family Functioning Profile in Adolescents at Clinical High Risk for Psychosis: Rigidity as a Possible Preventive Target.. *Frontiers in Psychiatry*, **2022**, 13, 861201	5